Aligos Therapeutics (NASDAQ:ALGS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holdersLight Up your Portfolio with Spark:Easily identify ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever 60.4% of Aligos Therapeutics shares are held by institutional investors.

We've identified the following companies as similar to Aligos Therapeutics Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics ...

Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. The ‘Trade of the Day ...

The company will henceforth be known as Whitehawk Therapeutics, it announced Tuesday. Its stock ticker will be updated accordingly: As of Wednesday, it will trade as “WHWK” on the Nasdaq ...

In a remarkable display of market confidence, Aligos Therapeutics Inc. stock has reached a 52-week high, touching $42.99 amidst a... In a remarkable display of market confidence, Aligos Therapeutics ...